Market capitalization | $1.35b |
Enterprise Value | $1.36b |
P/E (TTM) P/E ratio | negative |
P/B ratio (TTM) P/B ratio | 20.51 |
Dividend yield | 0.00% |
Last dividend (FY23) | $1.80 |
Revenue growth (TTM) Revenue growth | -100.00% |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-14.75m |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
4 Analysts have issued a Catalyst Biosciences, Inc. forecast:
4 Analysts have issued a Catalyst Biosciences, Inc. forecast:
Sep '23 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -15 -15 |
64%
64%
|
EBIT (Operating Income) EBIT | -15 -15 |
65%
65%
|
Net Profit | -44 -44 |
472%
472%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of novel medicines to address serious medical conditions. The company was founded on August 20, 2015 and is headquartered in South San Francisco, CA.
Head office | United States |
CEO | Han Ying |
Employees | 4 |
Founded | 1997 |
Website | www.gyretx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.